Neon Therapeutics (NASDAQ:NTGN) had its target price reduced by Morgan Stanley from $19.00 to $13.00 in a report published on Tuesday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other equities analysts have also recently weighed in on NTGN. Berenberg Bank dropped their price target on Lucara Diamond from C$1.60 to C$1.50 in a research note on Wednesday, March 27th. HC Wainwright initiated coverage on Precision BioSciences in a research note on Tuesday. They issued a buy rating and a $21.00 price target on the stock. Mizuho set a $21.00 price target on Neon Therapeutics and gave the stock a buy rating in a research note on Monday, July 1st. Finally, Zacks Investment Research raised Golub Capital BDC from a hold rating to a buy rating and set a $20.00 price target on the stock in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $16.00.

NTGN traded down $0.31 during trading on Tuesday, reaching $3.82. The company had a trading volume of 5,599 shares, compared to its average volume of 193,300. The company has a 50-day moving average of $4.70. The firm has a market capitalization of $122.39 million and a P/E ratio of -0.66. Neon Therapeutics has a 12-month low of $4.08 and a 12-month high of $13.00. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.09.

Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.73) by ($0.03). Analysts anticipate that Neon Therapeutics will post -2.69 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace North America L.P. acquired a new position in shares of Neon Therapeutics during the first quarter valued at $49,000. Acadian Asset Management LLC bought a new stake in shares of Neon Therapeutics in the first quarter worth about $268,000. Rhumbline Advisers bought a new stake in shares of Neon Therapeutics in the first quarter worth about $78,000. Oppenheimer & Co. Inc. bought a new stake in shares of Neon Therapeutics in the first quarter worth about $194,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Neon Therapeutics by 100.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,000 shares of the company’s stock worth $65,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 69.57% of the company’s stock.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Story: How Do You Make Money With Penny Stocks?

Analyst Recommendations for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.